European Acute Cardiac Diagnostics Market

Point-of-care testing (POCT) provides a panel of cardiac tests that have been received successfully by end users, promoting growth for this segment and eventually for the overall market, according to a new report from Frost & Sullivan (Palo Alto, CA, USA), an international consulting firm.

As troponin testing becomes routine, the demand for decentralized testing from the POCT segment will increase. With expansion of the use of POCT in the cardiac testing market, larger companies will develop compact bench devices. Technologies capable of linking satellite hospital equipment, such as POC diagnostic devices, to central laboratory care information systems, will promote the uptake of POCT in acute cardiac care diagnostics. Dr. Fiona Rahman, a healthcare analyst with Frost & Sullivan, noted that integration of POCT systems into a hospital environment will encourage ease of data management.

Technical improvements that increase the availability of cardiac marker tests are expected to encourage the growth of the European acute cardiac marker diagnostics market. Faster analyzers, which are easier to use, can integrate patient information and compile a database based on patient medical histories, test ordering, and demographic data. Antibodies that detect proteins are becoming more sensitive to cardiac tissue. Automation has improved the technical performance of assays and has reduced costs. These technical advancements will result in a greater demand for cardiac markers.

Government backing actively promoting the use of new markers has further strengthened domestic markets in Germany, France, and the United Kingdom. Manufacturers will need to educate end-users about their products or recruit professionals such as cardiologists and physicians. Interfacing between clinicians, laboratory technicians, cardiologists, administrators, and product specialists will encourage acceptance of cardiac markers.



Related Links:
Frost & Sullivan